- Home
- CGTL vs SAVA Comparison
CGTL vs SAVA Comparison
Compare CGTL & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- SAVA
- Stock Information
- Founded
- CGTL 2016
- SAVA 1998
- Country
- CGTL Hong Kong
- SAVA United States
- Employees
- CGTL N/A
- SAVA N/A
- Industry
- CGTL
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CGTL
- SAVA Health Care
- Exchange
- CGTL NYSE
- SAVA Nasdaq
- Market Cap
- CGTL 70.3M
- SAVA 137.2M
- IPO Year
- CGTL 2024
- SAVA N/A
- Fundamental
- Price
- CGTL $5.38
- SAVA $1.27
- Analyst Decision
- CGTL
- SAVA Buy
- Analyst Count
- CGTL 0
- SAVA 3
- Target Price
- CGTL N/A
- SAVA $54.50
- AVG Volume (30 Days)
- CGTL 197.9K
- SAVA 2.2M
- Earning Date
- CGTL 05-15-2025
- SAVA 05-09-2025
- Dividend Yield
- CGTL N/A
- SAVA N/A
- EPS Growth
- CGTL 35.72
- SAVA N/A
- EPS
- CGTL 0.21
- SAVA N/A
- Revenue
- CGTL $35,611,761.00
- SAVA N/A
- Revenue This Year
- CGTL N/A
- SAVA N/A
- Revenue Next Year
- CGTL N/A
- SAVA N/A
- P/E Ratio
- CGTL $19.38
- SAVA N/A
- Revenue Growth
- CGTL N/A
- SAVA N/A
- 52 Week Low
- CGTL $2.80
- SAVA $1.25
- 52 Week High
- CGTL $10.59
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- SAVA 22.21
- Support Level
- CGTL N/A
- SAVA $1.63
- Resistance Level
- CGTL N/A
- SAVA $1.79
- Average True Range (ATR)
- CGTL 0.00
- SAVA 0.18
- MACD
- CGTL 0.00
- SAVA -0.13
- Stochastic Oscillator
- CGTL 0.00
- SAVA 1.11
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.